Summary
Centrexion Therapeutics has filed to raise $86.25 million in an IPO from the sale of its common stock.
The firm is advancing a pipeline of acute and chronic pain treatments.
When we learn more details from management about its pricing and valuation expectations, I'll provide a final opinion.
This idea was discussed in more depth with members of my private investing community, IPO Edge. Start your free trial today »

Quick Take
Centrexion Therapeutics (CNTX) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement.
The firm is developing medication for moderate to severe chronic pain.
CNTX is in Phase 3 trials for three programs for its lead candidate. The firm has had promising results so far but faces a challenging and expensive road ahead.
I’ll provide an update when we learn more IPO details from management.

